Solaris Pharma Corp Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SOLARIS PHARMA CORP
SOLARIS PHARMA CORP has ten approved drugs.
Summary for Solaris Pharma Corp
| US Patents: | 0 |
| Tradenames: | 7 |
| Ingredients: | 7 |
| NDAs: | 10 |
| Patent Litigation for Solaris Pharma Corp: | See patent lawsuits for Solaris Pharma Corp |
Drugs and US Patents for Solaris Pharma Corp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solaris Pharma Corp | ESTRADIOL | estradiol | GEL;TRANSDERMAL | 217863-005 | Jul 12, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Solaris Pharma Corp | NEOMYCIN SULFATE | neomycin sulfate | TABLET;ORAL | 065220-001 | Jul 28, 2006 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Solaris Pharma Corp | ESTRADIOL | estradiol | GEL;TRANSDERMAL | 217863-003 | Jul 12, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Solaris Pharma Corp | TAZAROTENE | tazarotene | GEL;TOPICAL | 213644-001 | Mar 20, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Solaris Pharma Corp | TAZAROTENE | tazarotene | CREAM;TOPICAL | 214560-001 | Nov 24, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Solaris Pharma Corp | ESTRADIOL | estradiol | GEL;TRANSDERMAL | 217863-004 | Jul 12, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

